AUTHORS
Aharon Golod, MD, Luke Foley, MD2, Tobias Tix, MD3, Philip Thompson, MB, BS4, John F. Seymour, MBBS, PhD5, Edward R. Scheffer Cliff, MD, MPH6
AFFILIATIONS
1 Peter Maccallum Cancer Centre, Melbourne CBD, Victoria, Australia
2 Saint Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
3 Klinikum der Universität München, München, Germany
4 Peter Maccallum Cancer Centre, Melbourne CBD, Victoria, Australia
5 Peter Maccallum Cancer Centre, Melbourne CBD, Victoria, Australia
6 Peter Maccallum Cancer Centre, Melbourne CBD, Victoria, Australia
ABSTRACT
Introduction
In the treatment of B-cell malignancies such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), second-generation cBTKis acalabrutinib (acala) and zanubrutinib (zanu) and the non-covalent BTKi pirtobrutinib (pirto) have all demonstrated improved toxicity profiles compared to first-generation cBTKi ibrutinib. Although pirto offered improved tolerability compared with ibrutinib in the randomized BRUIN CLL-314 trial, it has not yet been directly compared with acala or zanu. Pirto’s narrower kinome may reduce off-target adverse events (AEs), and clinicians must therefore consider which BTKi offers patients the best safety profile. We performed a systematic review and meta-analysis of prospective trials to estimate agent-specific AE incidence among BTKis.
Methods
PubMed and Ovid Embase were searched up to 21 June 2026 (PROSPERO CRD420261385014). Prospective trials and prospective observational studies of ≥30 patients were included if ≥1 arm comprised pirto, acala or zanu alone or with a BCL-2 inhibitor and/or anti-CD20 antibody; pilot studies, expanded-access cohorts and indirect comparisons were excluded. The unit of analysis was the treatment cohort; proportions used the safety analysis set. Monotherapy and combination cohorts were analysed separately, with BTKi monotherapy across CLL/SLL and MCL prespecified as the primary comparison. Follow-up adjusted analyses included only cohorts reporting median follow-up. Incidence was pooled by random-effects random-intercept logistic regression, with the Q test for between-agent differences and meta-regression of logit incidence on median follow-up with agent as covariate.
Results
Of 2,095 records screened, 33 publications contributed 38 non-overlapping cohorts from 26 trials and 4,485 patients. The primary population, BTKi monotherapy in CLL/SLL and MCL, comprised 24 cohorts and 3,301 patients, balanced across agents (acala 1,261, pirto 1,067, zanu 973); 14 cohorts (1,184 patients) received combinations. Median follow-up was 21.8 months for pirto, 36.4 mo for acala and 39.3 mo for zanu, and was not reported for 3 cohorts.
Unadjusted pooled incidence (denominators varied by endpoint), for pirto, acala and zanu, respectively, were: any-grade infection 59.8% (95% CI, 48.3-70.3), 74.6% (67.5-80.7) and 78.7% (70.9-85.0), p=0.013; grade ≥3 adverse events 51.0%, 60.0% and 64.0%, p=0.12; any-grade hypertension 10.4%, 7.2% and 16.3%, p=0.06; discontinuation for adverse events 9.1%, 13.7% and 11.2%, p=0.14. Grade ≥3 neutropenia was highest with zanu (20.5%) and lowest with acala (14.6%), with pirto intermediate (18.5%, p=0.1).
Median follow-up for pirto cohorts (21.8 months) was substantially less than acala (36.4) or zanu (39.3). After adjusting for follow-up duration, infection incidence was similar between agents (odds ratio (OR) pirto versus acala 0.84, 95% CI 0.49-1.44; pirto versus zanu 0.61, 0.36-1.06), and no key endpoint distinguished pirto from either covalent BTKi. Zanu was associated with higher reported odds of hypertension than acala [any-grade (OR 2.39, 1.45-3.95), grade ≥3 (OR 2.91, 1.41-6.01)]. Atrial fibrillation did not differ between agents (grade ≥3, pirto versus acala 0.91, 0.22-3.89; pirto versus zanu 0.68, 0.18-2.54).
In combinations, grade ≥3 neutropenia with a BCL-2 inhibitor was 32.3% with acala (n=291), 22.8% with zanu (n=114) and 46.7% with pirto (n=15); for BTKi plus BCL-2i plus anti-CD20 it was: acala 43.8% (n=377), zanu 19.8% (n=106) and pirto 60.0% (n=10), respectively. Only acala contributed BTKi plus anti-CD20 cohorts (271 patients; neutropenia 15.1%). Pirto contributed only 25 patients in 2 early-phase cohorts.
Reporting was incomplete and asymmetric. Serious adverse events and second primary malignancy were reported only by cBTKi cohorts, and total grade ≥3 rates were missing for 13 of 38 cohorts. No pirto cohort reported major bleeding as an endpoint, bleeding instead being captured as a composite.
Conclusions
Although pirto showed numerically lower reported AE incidence than acala or zanu for most endpoints, differences were attenuated after controlling for follow-up. These findings suggest that the narrower kinome of pirtobrutinib has not yet demonstrated a clear safety advantage over second-generation cBTKis although interpretation is limited by differences in trial populations, including prior therapies and baseline patient characteristics. Among cBTKis, zanu demonstrated higher reported hypertension incidence than acala.
DISCLOSURES
Aharon Golod, MD: No relevant conflicts of interest to declare.